IUPAC/Chemical Name
(S)-N-((S)-1-((S)-2-carbamoylpyrrolidin-1-yl)-4-methyl-1-oxopentan-2-yl)-5-oxopyrrolidine-2-carboxamide
InChi Key
WKRBQSKJRZKXAH-SRVKXCTJSA-N
InChi Code
InChI=1S/C16H26N4O4/c1-9(2)8-11(19-15(23)10-5-6-13(21)18-10)16(24)20-7-3-4-12(20)14(17)22/h9-12H,3-8H2,1-2H3,(H2,17,22)(H,18,21)(H,19,23)/t10-,11-,12-/m0/s1
SMILES Code
O=C(N)[C@H]1N(C([C@H](CC(C)C)NC([C@H](CC2)NC2=O)=O)=O)CCC1
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.03.00
Preparing Stock Solutions
The following data is based on the
product
molecular weight
338.40
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Seki M. [Determination of LH in the urine by Luteonosticon]. Nihon Sanka Fujinka Gakkai Zasshi. 1972 Apr;24(4):285-7. Japanese. PubMed PMID: 5065484.
2: Ruffié A, Dubecq JP. [1st trials of Luteonosticon]. Bull Fed Soc Gynecol Obstet Lang Fr. 1971 Apr-May;23(2):153. French. PubMed PMID: 5121058.
3: Seki M. [Semi-quantitative analysis of urinary HCG by Luteonosticon]. Nihon Sanka Fujinka Gakkai Zasshi. 1972 Jan;24(1):69-72. Japanese. PubMed PMID: 4335311.
4: Hepp H, Schneller B. [Studies with the immunological LH test Luteonosticon in clinical practice]. Arch Gynakol. 1971 Jun 4;211(1):219-20. German. PubMed PMID: 5108855.
5: Sîrbu P, Cioltei A, Marinescu AD, Stăncescu S, Dumbrăvescu A. [Luteonosticon monitoring of spontaneous and clomiphene or gonadotrophin stimulated cycles]. Acta Eur Fertil. 1974 Sep;5(3):275-86. English, French. PubMed PMID: 4446895.
6: Hohlweg W. [Clinical value of luteonosticon test]. Wien Klin Wochenschr. 1973 Mar 16;85(11):165-7. German. PubMed PMID: 4691815.
7: van Veen WA, Eskes TK, Heck YS, Salcedo L, Kool MJ. [Metastatic trophoblastic tumor; a patient studied by means of the immunochemical LH test (luteonosticon test)]. Ned Tijdschr Geneeskd. 1972 Dec 23;116(52):2371-2. Dutch. PubMed PMID: 4345007.
8: Kemeter P, Wögerbauer C, Gring H, Salzer H, Friedrich F, Breitenecker G. [The correlation between lh determination in the urine (Luteonosticon and JI-Gonavis) and serum LH, FSH, oestradiol, progesterone, testosterone and prolactin levels at midcycle. (author's transl)]. Wien Klin Wochenschr. 1979 Feb 16;91(4):118-22. German. PubMed PMID: 425530.
9: Bressensdorf DB, Knorr D. [Normal values of LH and FSH excretion in the urine of children and juveniles by the luteonosticon and FSH-nosticon test (author's transl)]. Klin Padiatr. 1978 Jul;190(4):383-8. German. PubMed PMID: 566820.
